



- (51) **International Patent Classification:**
C07K 16/28 (2006.01) *A61K 45/06* (2006.01)
- (21) **International Application Number:**
PCT/US2017/039810
- (22) **International Filing Date:**
28 June 2017 (28.06.2017)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/356,105 29 June 2016 (29.06.2016) US
- (71) **Applicant:** CHECKPOINT THERAPEUTICS, INC.
[US/US]; 2 Gansevoort Street, 9th Floor, New York, NY 10014 (US).
- (72) **Inventors:** BELK, Jonathan; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, NH 03766 (US). SHARKEY, Nathan, J.; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, NH 03766 (US). GORELIK, Leonid; 69 Winston Road, Newton, MA 02459 (US).
- (74) **Agent:** VILLACORTA, Gilberto, M. et al.; Foley & Lardner LLP, 3000 K Street NW, Suite 600, Washington, DC 20007 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM,


AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

- (54) **Title:** PD-L1-SPECIFIC ANTIBODIES AND METHODS OF USING THE SAME



	Clinical control mAb	CTI-048	Negative control mAb
IC50	0.4909	0.1941	~ 0.0

FIGURE 5

- (57) **Abstract:** The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-L1 and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.